[Exploratory study of macromomycin].
Macromomycin, a new antitumor antibiotic (NSC-170105) with significant antitumor activity in animal tumor systems, was administered to 18 patients in an exploratory study. The dose ranged from 1mg to 30 mg per body with a single dose was given. The toxic effects included delayed type leukopenia and thrombocytopenia with nadir of 4 weeks. Except mild upper GI disturbance, no pulmonary, cardiac, hepatic, renal or CNS toxicity was observed. No anaphylaxis was observed in this study. MTD of macromomycin considered to be 26 mg/m2 and optimal administration schedule will be 20 mg/m2 every 6 weeks. Antitumor activity was detected in one patient with ovarian carcinoma with MR in short period.
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010455:Peptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D010455:Peptides; C001666:auromomycin